Product Description
Novartis is developing HRO761, an oral drug that acts on a protein called Werner (WRN), which may contribute to cancer growth. By acting on WRN, HRO761 may be able to stop the growth of the cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05838768)
Mechanisms of Action: WRN Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, France, Germany, Israel, Italy, Japan, Korea, Norway, Singapore, Spain, Sweden, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CHRO761A12101 | P1 |
Recruiting |
Colorectal Cancer |
2029-05-30 |
|
| jRCT2031230088 | P1 |
Recruiting |
Colorectal Cancer |
2027-02-28 |